8月27日,上海医药发布2026年半年度报告。上半年,公司实现营业收入1474.7亿元,同比增长4.15%;归属于上市公司股东的净利润为35.04亿元,同比下降21.4%;归属于上市公司股东的扣除非经常性损益的净利润为24.77亿元,同比增长17.98%。 半年报显示,上半年公司归母净利润同比下降,主要是受到一次性特殊损益的波动影响,剔除一次性特殊损益后的归母净利润为28.28亿元,同比增长...
Source Link8月27日,上海医药发布2026年半年度报告。上半年,公司实现营业收入1474.7亿元,同比增长4.15%;归属于上市公司股东的净利润为35.04亿元,同比下降21.4%;归属于上市公司股东的扣除非经常性损益的净利润为24.77亿元,同比增长17.98%。 半年报显示,上半年公司归母净利润同比下降,主要是受到一次性特殊损益的波动影响,剔除一次性特殊损益后的归母净利润为28.28亿元,同比增长...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.